Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
,aspect=ignore)
Medscape Nurses
Di Tomo P, Lanuti P, Di Pietro N, Baldassarre MPA, Marchisio M, Pandolfi A, et al
The saline composition and bacteriostatic preservative system work together to support the stability of sensitive compounds during storage and in vitro experimentation
US$ 25.72
US$ 22.56
US$ 21.80
US$ 29.35
US$ 24.14
US$ 21.04
US$ 25.93
US$ 21.79
US$ 25.76
